Compare SRL & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRL | ACOG |
|---|---|---|
| Founded | 2017 | 2000 |
| Country | China | Canada |
| Employees | N/A | 57 |
| Industry | Professional Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.5M | 110.4M |
| IPO Year | 1996 | N/A |
| Metric | SRL | ACOG |
|---|---|---|
| Price | $6.13 | $5.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 12.8K | ★ 33.9K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | ★ 16.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $139.22 |
| Revenue Next Year | N/A | $134.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.13 | $4.50 |
| 52 Week High | $10.39 | $10.88 |
| Indicator | SRL | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 28.74 | 47.54 |
| Support Level | $5.37 | $5.73 |
| Resistance Level | $6.44 | $6.48 |
| Average True Range (ATR) | 0.35 | 0.40 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 48.57 | 50.43 |
Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.